There is no sign of a slowdown in Johnston County's rapid growth, meaning things like cost of living and infrastructure are ...

Clayton Kershaw isn’t going anywhere. The Los Angeles Dodgers are apparently close to signing a new deal with the longtime pitcher, who was spotted at the team's spring training facility on ...

A breakthrough in weight loss medication is on the horizon. While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient ...

As long as longtime pitcher Clayton Kershaw, 36, remains a free agent, the unimaginable could still happen for Los Angeles Dodgers fans. A two-time World Series champion and a three-time Cy Young ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

A Los Angeles Dodgers team without Clayton Kershaw on the roster doesn't seem right. Kershaw, a sure Hall of Famer and one of the best to ever lace them up, is more than just a pitcher for the ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes and weight loss medicines, including Wegovy and ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...